Tocolytic Agents Market to a Steady Revenue CAGR of 5.3% by 2031 | Growth Plus Reports
Growth Plus Reports
5 min read
Growth Plus Reports
Newark, New Castle, USA, May 09, 2023 (GLOBE NEWSWIRE) -- Growth Plus Reports estimated the size of the global market fortocolytic agents in 2022, and it is expected to increase at a revenue CAGR of5.3% by 2031.
The global market for tocolytic agents was analyzed and is expected to rise significantly in terms of revenue share during the forecast period. A family of drugs known as tocolytic medicines are used to treat or prevent preterm labor and delivery. If untreated, preterm delivery can result from the development of regular uterine contractions before the 37th week of pregnancy. Premature labor is characterized as this.
Key Takeaways:
The increasing number of preterm deliveries is driving the market revenue share.
Enhanced safety and effectiveness are driving the market demand.
The demand for combination therapies is increasing the market revenue growth rapidly.
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
Recent Development in the Tocolytic Agents Market:
In August 2021, Organon & Co. and ObsEva SA collaborated to create, develop, and market OBE022 (ebopiprant). Ebopiprant is a once-daily, oral, selective prostaglandin F2 receptor antagonist that can potentially be a first-in-class medication. It is intended to control preterm labor by reducing inflammation, reducing uterine contractions, preventing cervical changes, and preventing rupture of the fetal membranes without having the potentially harmful side effects on the fetus that are associated with non-specific prostaglandin synthesis inhibitors (NSAIDs).
Competitive Landscape
A list of the prominent players operating in the global market for tocolytic agents includes:
Pfizer Inc.
Merck & Co., Inc.
Apotex Inc
Bayer AG
Astra Zeneca Plc
Market Drivers and Restraints:
The global tocolytic agents market revenue is driven by the rising increasing demand for laryngoscopes in emergency medical services, advancements in technology, and growing awareness of lacrimal gland and tear duct disorders.
However, due to the lack of awareness and high expenses, the tocolytic agents' market revenue growth is expected to be restrained.
Market Segmentation:
Based on drug class, the tocolytic agents market is segmented into magnesium sulfate, betamimetics, oxytocin antagonists, calcium channel inhibitors, prostaglandin inhibitors, and others.
Based on the route of administration, the tocolytic agents market is segmented into oral and parenteral.
Segmentation By Drug Class
Based on the drug class, the prostaglandin inhibitors segment dominates the global tocolytic agents market with the largest revenue share. This large revenue share is attributed to the remarkable effectiveness in lowering the frequency of preterm labor and postponing delivery. Furthermore, they are widely preferred for rapidly inhibiting uterine contractions in preterm delivery.
Based on the region, North America, with the largest revenue share, dominates the global tocolytic agents market. This lion's share is attributed to the rising number of preterm birth in North America and the increase in the demand for tocolytic agents due to their accessibility and availability in this region.
Report Coverage
Global sales of tocolytic drugs were thoroughly researched by Growth Plus Reports. We looked at the basic market traits, important investment spheres, regional growth analytics, revenue projections, rival market participants, and mergers and acquisitions.
Table of Content
INTRODUCTION
Market Ecosystem
Timeline Under Consideration
Historical Years – 2021
Base Year – 2022
Forecast Years – 2023 to 2031
Currency Used in the Report
RESEARCH METHODOLOGY
Research Approach
Data Collection Methodology
Data Sources
Secondary Sources
Primary Sources
Market Estimation Approach
Bottom Up
Top Down
Market Forecasting Model
Limitations and Assumptions
PREMIUM INSIGHTS
Current Market Trends (COVID-19 Perspective)
Key Players & Competitive Positioning (2022)
Regulatory Landscape
MARKET DYNAMICS
Drivers
Restraints/Challenges
Opportunities
GLOBAL TOCOLYTIC AGENTS MARKET- ANALYSIS & FORECAST, BY DRUG CLASS
Magnesium Sulfate
Betamimetics
Oxytocin Antagonists
Calcium Channel Inhibitors
Prostaglandin Inhibitors
Others
GLOBAL TOCOLYTIC AGENTS MARKET- ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION
Minimally Invasive Spine Technologies Market by Type (Percutaneous Pedicle Screw-Rod Fixation, Trans-sacral Fixation), Indication (Herniated Disc, Degenerative Disc Disease), End User (Hospitals, Orthopedic Clinics) – Global Outlook & Forecast 2023-2031
Smart Healthcare Market by Product (mHealth, RFID Kanban Systems), Application (Storage & Inventory Management, Monitoring) - Global Outlook and Forecast 2023-2031
Immunostimulants Market by Type (Vaccines, Interferons, Interleukins, Colony Stimulating Factor), Indications (Cancer, Immunodeficiency Disorder, and Organ Transplantations) – Global Outlook & Forecast 2023-2031
Veterinary Forceps Market by Type (Thumb Forceps, Hemostatic Forceps, Tissue Forceps, Other), En User (Veterinary Hospitals and Veterinary Clinics) – Global Outlook & Forecast 2021-2031
Hand Eczema Treatment Market by Drug Class (Topical Steroids, Calcineurin Inhibitors), Formulations (Creams & Lotions, Ointments), End User (Retail Pharmacies, Hospital Pharmacies) – Global Outlook & Forecast 2023-2031
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
